1	2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Typical	_	_	JJ	_	_	_	_	_
2	Ligands	_	_	NNS	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	Bile	_	_	NNP	_	_	_	_	_
5	Acids	_	_	NNP	_	_	_	_	_


1	BA	_	_	NNP	_	_	_	_	_
2	targeted	_	_	VBN	_	_	_	_	_
3	therapy	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	based	_	_	VBN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	their	_	_	PRP$	_	_	_	_	_
8	receptors	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	ligands	_	_	NNS	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	regulation	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	BAs	_	_	NN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	other	_	_	JJ	_	_	_	_	_
7	pathways	_	_	NNS	_	_	_	_	_
8	occurs	_	_	VBZ	_	_	_	_	_
9	mainly	_	_	RB	_	_	_	_	_
10	through	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	activation	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	nuclear	_	_	JJ	_	_	_	_	_
15	hormone	_	_	NN	_	_	_	_	_
16	receptors	_	_	NNS	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	NHRs	_	_	NNS	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	such	_	_	JJ	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	farnesoid	_	_	NN	_	_	_	_	_
24	X	_	_	NN	_	_	_	_	_
25	receptor	_	_	NN	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	FXR	_	_	NN	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	pregnane	_	_	NN	_	_	_	_	_
31	X	_	_	NN	_	_	_	_	_
32	receptor	_	_	NN	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	PXR	_	_	NN	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	vitamin	_	_	NN	_	_	_	_	_
39	D	_	_	NN	_	_	_	_	_
40	receptor	_	_	NN	_	_	_	_	_
41	(	_	_	-LRB-	_	_	_	_	_
42	VDR	_	_	NN	_	_	_	_	_
43	)	_	_	-RRB-	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	activation	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	receptors	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	it	_	_	PRP	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	necessary	_	_	JJ	_	_	_	_	_
11	that	_	_	IN	_	_	_	_	_
12	they	_	_	PRP	_	_	_	_	_
13	interact	_	_	VBP	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	retinoid	_	_	JJ	_	_	_	_	_
17	X	_	_	NN	_	_	_	_	_
18	receptor	_	_	NN	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	heterodimer	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	RXR	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Afterwards	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	they	_	_	PRP	_	_	_	_	_
4	act	_	_	VBP	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	various	_	_	JJ	_	_	_	_	_
7	regulatory	_	_	JJ	_	_	_	_	_
8	regions	_	_	NNS	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	binding	_	_	VBG	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	hormone	_	_	NN	_	_	_	_	_
13	response	_	_	NN	_	_	_	_	_
14	elements	_	_	NNS	_	_	_	_	_
15	causing	_	_	VBG	_	_	_	_	_
16	several	_	_	JJ	_	_	_	_	_
17	genes	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	be	_	_	VB	_	_	_	_	_
20	up	_	_	RP	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	downregulated	_	_	VBN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	their	_	_	PRP$	_	_	_	_	_
25	transcription	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Most	_	_	JJS	_	_	_	_	_
2	BAs	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	secondary	_	_	JJ	_	_	_	_	_
6	BA	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	LCA	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	binding	_	_	VBG	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	FXR	_	_	NNP	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	PXR	_	_	NNP	_	_	_	_	_
17	respectively	_	_	RB	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	2.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	FXR	_	_	NNP	_	_	_	_	_


1	FXR	_	_	NNP	_	_	_	_	_
2	plays	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	important	_	_	JJ	_	_	_	_	_
5	role	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	BA	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	glucose	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	lipid	_	_	JJ	_	_	_	_	_
13	metabolism	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	most	_	_	RBS	_	_	_	_	_
4	highly	_	_	RB	_	_	_	_	_
5	expressed	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	liver	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	ileum	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	kidneys	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	adrenal	_	_	JJ	_	_	_	_	_
16	glands	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	strongest	_	_	JJS	_	_	_	_	_
3	activator	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	CDCA	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	followed	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	DCA	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	CA	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	LCA	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Despite	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	fact	_	_	NN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	LCA	_	_	NNP	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	weak	_	_	JJ	_	_	_	_	_
9	activator	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	FXR	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	very	_	_	RB	_	_	_	_	_
17	strong	_	_	JJ	_	_	_	_	_
18	downregulator	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	its	_	_	PRP$	_	_	_	_	_
21	function	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	thus	_	_	RB	_	_	_	_	_
24	could	_	_	MD	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	termed	_	_	VBN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	partial	_	_	JJ	_	_	_	_	_
29	agonist	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Controlling	_	_	VBG	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	synthesis	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	enterohepatic	_	_	JJ	_	_	_	_	_
6	circulation	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	BAs	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	represents	_	_	VBZ	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	major	_	_	JJ	_	_	_	_	_
13	function	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	FXR	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	liver	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	bile	_	_	NN	_	_	_	_	_
6	flow	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	prompted	_	_	VBN	_	_	_	_	_
9	through	_	_	IN	_	_	_	_	_
10	FXR	_	_	NNP	_	_	_	_	_
11	activation	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	being	_	_	VBG	_	_	_	_	_
3	activated	_	_	VBN	_	_	_	_	_
4	through	_	_	IN	_	_	_	_	_
5	BA	_	_	NNP	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	ileum	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	expression	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	fibroblast	_	_	NN	_	_	_	_	_
14	growth	_	_	NN	_	_	_	_	_
15	factor	_	_	NN	_	_	_	_	_
16	15/19	_	_	CD	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	FGF15/19	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	increases	_	_	VBZ	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	leading	_	_	VBG	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	an	_	_	DT	_	_	_	_	_
25	activation	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	fibroblast	_	_	NN	_	_	_	_	_
28	growth	_	_	NN	_	_	_	_	_
29	factor	_	_	NN	_	_	_	_	_
30	receptor	_	_	NN	_	_	_	_	_
31	4	_	_	CD	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	FGFR4	_	_	NN	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	hepatocytes	_	_	NNS	_	_	_	_	_
37	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	great	_	_	JJ	_	_	_	_	_
5	importance	_	_	NN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	FGF15/19	_	_	NNP	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	ileum-derived	_	_	JJ	_	_	_	_	_
11	enterokine	_	_	NN	_	_	_	_	_
12	that	_	_	WDT	_	_	_	_	_
13	governs	_	_	VBZ	_	_	_	_	_
14	BA	_	_	NN	_	_	_	_	_
15	homeostasis	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	regulates	_	_	VBZ	_	_	_	_	_
18	hepatic	_	_	JJ	_	_	_	_	_
19	glucose	_	_	NN	_	_	_	_	_
20	metabolism	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	stimulates	_	_	VBZ	_	_	_	_	_
24	protein	_	_	NN	_	_	_	_	_
25	synthesis	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	If	_	_	IN	_	_	_	_	_
2	administered	_	_	VBN	_	_	_	_	_
3	pharmacologically	_	_	RB	_	_	_	_	_
4	or	_	_	CC	_	_	_	_	_
5	expressed	_	_	VBN	_	_	_	_	_
6	transgenically	_	_	RB	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	mice	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	FGF19	_	_	NN	_	_	_	_	_
11	increases	_	_	VBZ	_	_	_	_	_
12	hepatic	_	_	JJ	_	_	_	_	_
13	lipid	_	_	NN	_	_	_	_	_
14	oxidation	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	reduces	_	_	VBZ	_	_	_	_	_
17	lipogenesis	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	protects	_	_	VBZ	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	hepatosteatosis	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	lack	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	it	_	_	PRP	_	_	_	_	_
5	causes	_	_	VBZ	_	_	_	_	_
6	impaired	_	_	VBN	_	_	_	_	_
7	liver	_	_	NN	_	_	_	_	_
8	regeneration	_	_	NN	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	lack	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	FGF	_	_	NNP	_	_	_	_	_
5	15	_	_	CD	_	_	_	_	_
6	results	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	increased	_	_	VBN	_	_	_	_	_
9	hepatic	_	_	JJ	_	_	_	_	_
10	steatosis	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	development	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	endoplasmic	_	_	JJ	_	_	_	_	_
17	reticulum	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	ER	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	stress	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	liver	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	mice	_	_	NNS	_	_	_	_	_
27	fed	_	_	VBD	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	high	_	_	JJ	_	_	_	_	_
30	fat	_	_	NN	_	_	_	_	_
31	diet	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	activation	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	FGFR4	_	_	NNP	_	_	_	_	_
5	together	_	_	RB	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	activation	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	small	_	_	JJ	_	_	_	_	_
11	heterodimer	_	_	NN	_	_	_	_	_
12	partner	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	SHP	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	liver	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	inhibits	_	_	VBZ	_	_	_	_	_
21	CYP7A1	_	_	NNP	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	order	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	downregulate	_	_	VB	_	_	_	_	_
5	CYP7A1	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	intestinal-specific	_	_	JJ	_	_	_	_	_
8	FXR	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	required	_	_	VBN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	other	_	_	JJ	_	_	_	_	_
4	hand	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	liver-specific	_	_	JJ	_	_	_	_	_
8	FXR	_	_	NNP	_	_	_	_	_
9	plays	_	_	VBZ	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	important	_	_	JJ	_	_	_	_	_
12	role	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	repression	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	expression	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	CYP8B1	_	_	NNP	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	mechanisms	_	_	NNS	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	BAs	_	_	NNP	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	suppress	_	_	VB	_	_	_	_	_
9	their	_	_	PRP$	_	_	_	_	_
10	own	_	_	JJ	_	_	_	_	_
11	synthesis	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	through	_	_	IN	_	_	_	_	_
14	FXR	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	FXR	_	_	NNP	_	_	_	_	_
2	influences	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	hepatic	_	_	JJ	_	_	_	_	_
5	lipid	_	_	NN	_	_	_	_	_
6	homeostasis	_	_	NN	_	_	_	_	_
7	via	_	_	IN	_	_	_	_	_
8	SHP	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	which	_	_	WDT	_	_	_	_	_
11	reduces	_	_	VBZ	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	expression	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	SREBP1	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	regulates	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	expression	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	peroxisome	_	_	NN	_	_	_	_	_
8	proliferator-activated	_	_	JJ	_	_	_	_	_
9	receptor	_	_	NN	_	_	_	_	_
10	PPAR-α	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	regulator	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	triglyceride	_	_	NN	_	_	_	_	_
16	metabolism	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	that	_	_	WDT	_	_	_	_	_
19	can	_	_	MD	_	_	_	_	_
20	induce	_	_	VB	_	_	_	_	_
21	free	_	_	JJ	_	_	_	_	_
22	fatty	_	_	NN	_	_	_	_	_
23	acid	_	_	NN	_	_	_	_	_
24	β-oxidation	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	2.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Takeda	_	_	NNP	_	_	_	_	_
2	G-Protein-Coupled	_	_	NNP	_	_	_	_	_
3	Receptor	_	_	NN	_	_	_	_	_
4	5	_	_	CD	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	TGR5	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_


1	TGR5	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	G-protein	_	_	NN	_	_	_	_	_
5	coupled	_	_	VBN	_	_	_	_	_
6	membrane	_	_	NN	_	_	_	_	_
7	receptor	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	BAs	_	_	NNP	_	_	_	_	_
10	activate	_	_	VBP	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	LCA	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	considered	_	_	VBN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	strongest	_	_	JJS	_	_	_	_	_
8	activator	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	TGR5	_	_	NNP	_	_	_	_	_
11	among	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	main	_	_	JJ	_	_	_	_	_
14	primary	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	secondary	_	_	JJ	_	_	_	_	_
17	BAs	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	widely	_	_	RB	_	_	_	_	_
4	expressed	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	body	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	example	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	gallbladder	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	ileum	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	colon	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	liver	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	not	_	_	RB	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	hepatocytes	_	_	NNS	_	_	_	_	_
24	though	_	_	RB	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	brown	_	_	JJ	_	_	_	_	_
28	adipose	_	_	NN	_	_	_	_	_
29	tissue	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	BAT	_	_	NN	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	nervous	_	_	JJ	_	_	_	_	_
35	system	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	muscle	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Besides	_	_	IN	_	_	_	_	_
2	being	_	_	VBG	_	_	_	_	_
3	involved	_	_	VBN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	BA	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	glucose	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	lipid	_	_	NN	_	_	_	_	_
11	metabolism	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	interestingly	_	_	RB	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	it	_	_	PRP	_	_	_	_	_
16	also	_	_	RB	_	_	_	_	_
17	plays	_	_	VBZ	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	role	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	increasing	_	_	VBG	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	induction	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	BAT	_	_	NN	_	_	_	_	_
26	expression	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	thermogenesis	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	energy	_	_	NN	_	_	_	_	_
31	release	_	_	NN	_	_	_	_	_
32	via	_	_	IN	_	_	_	_	_
33	browning	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	white	_	_	JJ	_	_	_	_	_
36	adipose	_	_	NN	_	_	_	_	_
37	tissue	_	_	NN	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	TGR5	_	_	NNP	_	_	_	_	_
2	knockout	_	_	NN	_	_	_	_	_
3	leads	_	_	VBZ	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	changed	_	_	VBN	_	_	_	_	_
7	BA	_	_	NN	_	_	_	_	_
8	composition	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	anti-inflammatory	_	_	JJ	_	_	_	_	_
12	properties	_	_	NNS	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	example	_	_	NN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	inhibiting	_	_	VBG	_	_	_	_	_
18	nuclear	_	_	JJ	_	_	_	_	_
19	factor	_	_	NN	_	_	_	_	_
20	kappa-light-chain-enhancer	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	activated	_	_	VBN	_	_	_	_	_
23	B	_	_	NN	_	_	_	_	_
24	cells	_	_	NNS	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	NF-κB	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	or	_	_	CC	_	_	_	_	_
29	LPS-induced	_	_	JJ	_	_	_	_	_
30	production	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	inflammatory	_	_	JJ	_	_	_	_	_
33	cytokines	_	_	NNS	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	macrophages	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	another	_	_	DT	_	_	_	_	_
3	experiment	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	TGR5	_	_	NNP	_	_	_	_	_
6	knockout	_	_	NN	_	_	_	_	_
7	mice	_	_	NNS	_	_	_	_	_
8	received	_	_	VBD	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	sleeve	_	_	NN	_	_	_	_	_
11	gastrectomy	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	shown	_	_	VBN	_	_	_	_	_
16	how	_	_	WRB	_	_	_	_	_
17	TGR5	_	_	NNP	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	important	_	_	JJ	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	order	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	decrease	_	_	VB	_	_	_	_	_
24	hepatic	_	_	JJ	_	_	_	_	_
25	steatosis	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	improve	_	_	VB	_	_	_	_	_
28	glucose	_	_	NN	_	_	_	_	_
29	control	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	increase	_	_	VB	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	energy	_	_	NN	_	_	_	_	_
35	expenditure	_	_	NN	_	_	_	_	_
36	post-surgery	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_

